P-(cyclohexylmethyl)phosphinic acid ethyl ester | 133457-82-6

• 分子结构分类: 有机化合物 - 有机磷化合物
• 英文名称: P-(cyclohexylmethyl)phosphinic acid ethyl ester
• 英文别名: ethyl (cyclohexylmethyl)phosphinate；O-ethyl (cyclohexylmethyl)phosphinate
• CAS: 133457-82-6
• 化学式: C₉H₁₉O₂P
• 分子量: 190.222
• InChiKey: HCKHQTAWNJRNSN-UHFFFAOYSA-N

物化性质

• 沸点：
  261.6±23.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.08
• 重原子数：
  12.0
• 可旋转键数：
  4.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.3
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  P-(cyclohexylmethyl)phosphinic acid ethyl ester 在 三甲基溴硅烷 、 sodium hydride 、 lithium diisopropyl amide 作用下， 以 二氯甲烷 为溶剂， 反应 44.25h， 生成 (3-amino-2-oxopropyl)(cyclohexylmethyl)phosphinic acid hydrobromide
  参考文献：
  名称：

  Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists

  摘要：

  In 1987, 25 years after the synthesis of the potent and selective GABA(B) agonist baclofen (1), Kerr et al.(5) described the first GABA(B) antagonist phaclofen 2. However, phaclofen and structurally similar derivatives 3-5 did not cross the blood-brain barrier and hence were inactive in vivo as central nervous system agents. As a consequence, the therapeutic potential of GABA(B) antagonists remained unclear. In exploring GABA and baclofen derivatives by replacing the carboxylic acid residue with various phosphinic acid groups, we discovered more potent and water soluble GABA(B) antagonists. Electrophysiological experiments in vivo demonstrated that some of the new compounds were capable of penetrating the blood-brain barrier after oral administration. Neurotransmitter release experiments showed that they interacted with several presynaptic GABA(B) receptor subtypes, enhancing the release of GABA, glutamate, aspartate, and somatostatin. The new GABA(B) antagonists interacted also with postsynaptic GABA(B) receptors, as they blocked late inhibitory postsynaptic potentials. They facilitated the induction of long-term potentiation in vitro and in, vivo, suggesting potential cognition enhancing effects. Fifteen compounds were investigated in Various memory and learning paradigms in rodents. Although several compounds were found to be active, only 10 reversed the age-related deficits of old rats in a multiple-trial one-way active avoidance test after chronic treatment. The cognition facilitating effects of 10 were confirmed in learning experiments in Rhesus monkeys. The novel GABA(B) antagonists showed also protective effects in various animal models of absence epilepsy.

  DOI：

  10.1021/jm00017a016
• 作为产物：
  描述：

  乙醇 、 1,1-diethoxyethyl(cyclohexylmethyl)phosphinic acid ethyl ester 在 三甲基氯硅烷 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 P-(cyclohexylmethyl)phosphinic acid ethyl ester
  参考文献：
  名称：

  Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists

  摘要：

  In 1987, 25 years after the synthesis of the potent and selective GABA(B) agonist baclofen (1), Kerr et al.(5) described the first GABA(B) antagonist phaclofen 2. However, phaclofen and structurally similar derivatives 3-5 did not cross the blood-brain barrier and hence were inactive in vivo as central nervous system agents. As a consequence, the therapeutic potential of GABA(B) antagonists remained unclear. In exploring GABA and baclofen derivatives by replacing the carboxylic acid residue with various phosphinic acid groups, we discovered more potent and water soluble GABA(B) antagonists. Electrophysiological experiments in vivo demonstrated that some of the new compounds were capable of penetrating the blood-brain barrier after oral administration. Neurotransmitter release experiments showed that they interacted with several presynaptic GABA(B) receptor subtypes, enhancing the release of GABA, glutamate, aspartate, and somatostatin. The new GABA(B) antagonists interacted also with postsynaptic GABA(B) receptors, as they blocked late inhibitory postsynaptic potentials. They facilitated the induction of long-term potentiation in vitro and in, vivo, suggesting potential cognition enhancing effects. Fifteen compounds were investigated in Various memory and learning paradigms in rodents. Although several compounds were found to be active, only 10 reversed the age-related deficits of old rats in a multiple-trial one-way active avoidance test after chronic treatment. The cognition facilitating effects of 10 were confirmed in learning experiments in Rhesus monkeys. The novel GABA(B) antagonists showed also protective effects in various animal models of absence epilepsy.

  DOI：

  10.1021/jm00017a016

文献信息

• P-subsituted propane-phosphinic acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US05190934A1

  公开（公告）日：1993-03-02

  Compounds of the formula I ##STR1## wherein either R.sub.1 is halogen, R.sub.1 ' is halogen or hydrogen and R.sub.2 and R.sub.2 ' denote hydrogen or R.sub.1 and R.sub.1 ' represent hydrogen, R.sub.2 is an aliphatic or aromatic radical and R.sub.2 ' is hydroxy or R.sub.2 and R.sub.2 ' together represent oxo, and wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms or, if R.sub.1 and R.sub.1 ' denote hydrogen, R.sub.2 represents an aromatic radical and R.sub.2 ' is hydroxy, R represents methyl, and their salts are useful as nootropics, antidepressants and/or anxiolytics. The can be manufacture by replacing any group R.sub.5 by hydrogen and/or converting any group Z.sub.0 into amino in a compound of formula II ##STR2## in which R, R.sub.1, R.sub.1 ', R.sub.2 and R.sub.2 ' have their previous significances, Z represents a protected or latent amino group Z.sub.0 and R.sub.4 denotes hydrogen or a hyddroxy-protective group R.sub.5, and wherein amino as a constituent of R and/or hydroxy R.sub.2 ' or oxo R.sub.2 +R.sub.2 ' may be present in a temporarily protected form.

  式I的化合物##STR1##中，R.sub.1为卤素，R.sub.1'为卤素或氢，R.sub.2和R.sub.2'表示氢或R.sub.1和R.sub.1'代表氢，R.sub.2为脂肪族或芳香基团，R.sub.2'为羟基或R.sub.2和R.sub.2'一起表示羰基，其中R表示具有2个或更多碳原子的脂肪族、环脂肪族、环脂肪族-脂肪族或芳基脂肪族基团，或者如果R.sub.1和R.sub.1'表示氢，则R.sub.2表示芳香基团，R.sub.2'为羟基，R表示甲基，它们的盐可用作脑功能增强剂、抗抑郁剂和/或抗焦虑剂。可以通过将任何基团R.sub.5替换为氢和/或将任何基团Z.sub.0转化为氨基来制备，其中R、R.sub.1、R.sub.1'、R.sub.2和R.sub.2'具有其先前的含义，Z表示受保护或潜在的氨基团Z.sub.0，R.sub.4表示氢或羟基保护基团R.sub.5，氨基作为R的组分和/或羟基R.sub.2'或羰基R.sub.2+R.sub.2'可能以暂时受保护的形式存在于式II的化合物中##STR2##。
• N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids
  申请人：Ciba-Geigy Corporation

  公开号：US05332729A1

  公开（公告）日：1994-07-26

  N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids of formula I ##STR1## wherein R is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic or heteroarylaliphatic radical having at least 2 carbon atoms, R.sub.1 is hydrogen or hydroxy, R.sub.2 is an araliphatic or heteroarylaliphatic radical substituted by free or functionally modified carboxy that is bonded directly or by way of a spacer, and R.sub.3 is hydrogen, lower alkyl or a group R.sub.2, and the salts thereof have valuable nootropic and anti-epileptic properties and can be used in the preparation of a nootropic or anti-epileptic medicament.

  N-芳基和N-杂芳基氨基烷基膦酸的化学式I ##STR1## 其中R是至少有2个碳原子的脂肪烷基，环脂肪烷基，环脂肪烷基，芳基或杂芳基烷基基团，R.sub.1是氢或羟基，R.sub.2是通过自由或功能修饰的羧基取代的芳基或杂芳基烷基基团，该羧基直接或通过间隔连接，R.sub.3是氢，低碳基或R.sub.2基团，以及其盐具有有价值的智力增强和抗癫痫特性，并可用于制备智力增强或抗癫痫药物。
• Process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives
  申请人：Huang Bao-Guo

  公开号：US20050070507A1

  公开（公告）日：2005-03-31

  The present invention relates to a process for the preparation of 3-amino-2-hydroxypropylphosphinic acid derivatives of the formula I, which are valuable pharmaceutical active ingredients and can be used, for example, as antidepressants. The process starts from O-ethyl phosphinates of the formula II into which, after silylation with hexamethyldisilazane, the 3-amino-2-hydroxypropyl moiety is introduced by reactions with epichlorohydrin and ammonia.

  本发明涉及一种制备式I的3-氨基-2-羟基丙基膦酸衍生物的方法，这些衍生物是有价值的药用活性成分，例如可用作抗抑郁药。该过程从式II的O-乙基膦酸酯出发，经过与六甲基二硅氮烷硅化后，通过与环氧氯丙烷和氨反应引入3-氨基-2-羟基丙基基团。
• Substituted propane-phosphinic acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US05190933A1

  公开（公告）日：1993-03-02

  Compounds of the formula I ##STR1## wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, and wherein one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, in the case of R.sup.1 and R.sup.2, is hydroxy, and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or wherein R denotes methyl, R.sub.1 denotes hydrogen or hydroxy, R.sub.2 denotes an aromatic radical and R.sub.3 represents hydrogen, and their salts have GABA.sub.B -antagonistic properties and can be used as GABA.sub.B -antagonists. They are obtained when in a compound of formula II ##STR2## in which R, R.sup.1, R.sup.2 and R.sup.3 have their previous significances, Z represents --NH.sub.2 and R.sup.4 denotes a hydroxy-protective group R.sup.5 or, when R.sup.1 and R.sup.3 denote hydrogen and R.sup.2 denotes hydrogen or alkyl, denotes an alkali metal or ammonium ion R.sup.6, or Z represents a protected or latent amino group Z.sup.o and R.sup.4 denotes hydrogen or a hydroxy-protective group R.sup.5, any group R.sup.5 or R.sup.6 is replaced by hydrogen, and/or any group Z.sup.o is converted into --NH.sub.2.

  公式I的化合物如下：##STR1## 其中R表示具有2个或更多碳原子的脂肪族，环脂族，环脂族-脂肪族或芳基脂肪族基团，其中R.sup.1，R.sup.2和R.sup.3中的一个表示氢或脂肪族，环脂族，芳基脂肪族或芳香族基团，另一个R.sup.1，R.sup.2和R.sup.3中的一个是氢或，在R.sup.1和R.sup.2的情况下，是羟基，而R.sup.1，R.sup.2和R.sup.3中的剩余一个是氢，或其中R表示甲基，R.sub.1表示氢或羟基，R.sub.2表示芳基基团，而R.sub.3表示氢，它们的盐具有GABA.sub.B-拮抗性质，并且可以用作GABA.sub.B-拮抗剂。当在化合物II的情况下获得它们时，化合物II的公式如下：##STR2## 其中R，R.sup.1，R.sup.2和R.sup.3具有其先前的意义，Z表示--NH.sub.2，而R.sup.4表示羟基保护基团R.sup.5或，当R.sup.1和R.sup.3表示氢，而R.sup.2表示氢或烷基时，表示碱金属或铵离子R.sup.6，或Z表示受保护或潜在的氨基团Z.sup.o，而R.sup.4表示氢或羟基保护基团R.sup.5，任何R.sup.5或R.sup.6基团被氢替换，和/或任何Z.sup.o基团被转化为--NH.sub.2。
• Aminoalkanephosphinic acids and salts thereof
  申请人：Ciba-Geigy Corporation

  公开号：US05500418A1

  公开（公告）日：1996-03-19

  Compounds of formula I ##STR1## wherein R is diethoxymethyl, R.sub.1 is hydrogen, R.sub.2 is pyrid-3-ylmethyl and R.sub.3 is hydrogen, or R is cyclohexylmethyl, R.sub.1 is hydrogen and R.sub.2 is quinolin-4-ylmethyl, or R.sub.1 is hydroxy and R.sub.2 is 3,4-methylenedioxybenzyl, 1-(3,4-methylenedioxyphenyl)ethyl, and R.sub.3 is hydrogen, or R is benzyl, R.sub.1 is hydroxy, R.sub.2 is 1-(3,4-methylenedioxyphenyl)ethyl, and R.sub.3 is hydrogen, and salts thereof have GABA.sub.B -antagonistic properties and can be used for the treatment of diseases responsive to GABA.sub.B -antagonists.

  化合物的结构式为I ##STR1## 其中，R为二乙氧甲基，R.sub.1是氢，R.sub.2是吡啶-3-基甲基，R.sub.3是氢，或R为环己基甲基，R.sub.1是氢，R.sub.2是喹啉-4-基甲基，或R.sub.1是羟基，R.sub.2是3,4-亚甲二氧基苄基，1-(3,4-亚甲二氧基苯基)乙基，R.sub.3是氢，或R是苄基，R.sub.1是羟基，R.sub.2是1-(3,4-亚甲二氧基苯基)乙基，R.sub.3是氢，以及其盐具有GABA.sub.B-拮抗作用，可用于对GABA.sub.B-拮抗剂响应性疾病的治疗。